Top 5 Vendors in the Global Antidiuretic Drugs Market 2019-2023 | TechnavioThe Associated Press
LONDON--(BUSINESS WIRE)--Jul 12, 2019--
The demand for desmopressin analogs is increasing from healthcare providers and patients because of the high efficacy of its different formulations. Desmopressin is an artificial form of vasopressin hormone which prevents dehydration and controls excess urination (polyuria) and increased thirst (polydipsia). Moreover, the availability of desmopressin analogs in different formulations such as tablets and nasal sprays is leading to increased adoption by end-users, thereby boosting the antidiuretic drugs market growth. Furthermore, this industry research report also presents a competitive analysis of the market by application (autoimmune diseases, urologic diseases, and other applications) and geography (Asia, Europe, North America, and ROW).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005016/en/
Technavio has released a new market research report on the global antidiuretic drugs market from 2019-2023. (Graphic: Business Wire)
Competitive vendor landscape
The global antidiuretic drugs market is highly competitive with major vendors such as Avadel, CSL Limited, Ferring B.V., Novartis AG, and Sanofi, competing based on price, quality, and product/service offerings.
“With the increasing geriatric population and old-age dependency ratio, the incidences of genitourinary conditions is expected to increase. This will lead to a growing demand for antidiuretic drugs for the treatment of autoimmune and urologic diseases. Thus, the rising geriatric population is expected to boost the demand for antidiuretic drugs and drive market growth during the forecast period,” says a senior analyst at Technavio
Top five antidiuretic drugs market vendors
Avadel operates through its pharmaceuticals segment with key offering NOCTIVA (desmopressin acetate), which is a synthetic analog of 8-arginine vasopressin, an endogenous pituitary hormone, also known as ADH. It is available as an oil-in-water emulsion at two dose strengths, 0.83 mcg and 1.66 mcg of desmopressin acetate per spray, for nasal administration.
CSL Limited runs its operations through two segments: CSL Behring and Seqirus. Its key offerings include Stimate (desmopressin acetate), which is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). The Stimate nasal spray contains 1.5 mg/mL desmopressin acetate in an aqueous solution at a pH of approximately 5.0.
Ferring B.V. runs its operations through two segments: R&D services and other services. The company’s key offerings include DDAVP, MINIRIN, and NOCDURNA.
Novartis AG runs its operations through three segments: innovative medicines, Sandoz, and Alcon. The company’s key offering includes SYNTOCINON. SYNTOCINON injection contains oxytocin, which is a naturally-occurring hormone. The oxytocin available in the injection is human-made but works in the same way as the natural hormone.
Sanofi runs its operations through three segments: pharmaceuticals, consumer healthcare, and vaccines. The company’s key offering includes DDAVP Rhinal Tube. DDAVP Rhinal Tube (desmopressin acetate) is a synthetic analog of the natural pituitary hormone, 8-arginine vasopressin. It is provided as an aqueous solution for intranasal use.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Open-Angle Glaucoma Therapeutics market 2019-2023 - The market research study identifies Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc., as the leading players in the global open-angle glaucoma therapeutics market.
- Global Japanese Encephalitis Vaccines Market 2019-2023 - The market research study identifies Bharat Biotech Ltd., Biological E. Ltd., Green Cross Corp., Sanofi, and Valneva SE., as the leading players in the global Japanese encephalitis vaccines market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190712005016/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: CONSUMER HEALTH SENIORS PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 07/12/2019 05:00 AM/DISC: 07/12/2019 05:00 AM